Lexicon Stock Financials

LXRX
 Stock
  

USD 2.26  0.12  5.61%   

Lexicon Pharmaceuticals Revenue Per Employee is fairly stable at the moment as compared to the past year. Lexicon Pharmaceuticals reported Revenue Per Employee of 3,425 in 2021. Average Assets is likely to rise to about 234.9 M in 2022, whereas Net Income Per Employee is likely to drop (1.1 M) in 2022.
  
With this module, you can analyze Lexicon financials for your investing period. You should be able to track the changes in Lexicon Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Lexicon Most Recent Estimates

Quarterly Earnings Growth YOY
(0.63) 
EPS Estimate Next Quarter
(0.14) 
Diluted Eps
(0.61) 
EPS Estimate Current Year
(0.59) 
EPS Estimate Next Year
(0.60) 
EPS Estimate Current Quarter
(0.14) 
Understanding current and past Lexicon Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lexicon Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Lexicon Pharmaceuticals' assets may result in an increase in income on the income statement.

Revenues

305,842

The financial analysis of Lexicon Pharmaceuticals is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Lexicon Pharmaceuticals includes many different criteria found on its balance sheet. For example, investors should never minimize Lexicon Pharmaceuticals' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Lexicon Pharmaceuticals' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals Cash

Chance Of Financial Distress
Less than 23
Lexicon Pharmaceuticals has less than 23 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Lexicon Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Lexicon Pharmaceuticals' official financial statements usually reflect Lexicon Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lexicon Pharmaceuticals. For example, before you start analyzing numbers published by Lexicon accountants, it's critical to develop an understanding of what Lexicon Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Lexicon Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lexicon Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lexicon Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lexicon Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Lexicon Pharmaceuticals' management to manipulate its earnings.

Lexicon Pharmaceuticals Company Summary

Lexicon Pharmaceuticals competes with Northwest Healthcare, and Anheuser Busch. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceutcl operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001062822
ISINUS5288723027
RegionNorth America
Business Address2445 Technology Forest
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.lexpharma.com
Phone281 863 3000
CurrencyUSD - US Dollar
You should never invest in Lexicon Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Lexicon Stock, because this is throwing your money away. Analyzing the key information contained in Lexicon Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Lexicon Pharmaceuticals Key Financial Ratios

Generally speaking, Lexicon Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Lexicon Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Lexicon Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Lexicon Pharmaceuticals reports annually and quarterly.

Lexicon Pharmaceuticals Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Lexicon Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(122.99 M)(120.55 M)130.13 M(58.57 M)(87.76 M)(94.69 M)
Gross Profit89.79 M60.72 M318.84 M22.07 M298 K305.84 K
Interest Expense6.98 M20.78 M20.68 M14.54 M802 K823.11 K
Net Income(129.05 M)(120.55 M)130.13 M(58.57 M)(87.76 M)(94.69 M)
Operating Expenses218.31 M164 M177.4 M69.87 M87.39 M124.1 M
Operating Income(136.68 M)(103.28 M)141.44 M(180.38 M)(87.09 M)(93.97 M)
Revenues90.33 M63.21 M322.07 M24 M298 K305.84 K

Lexicon Pharmaceuticals Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Lexicon Pharmaceuticals. It measures of how well Lexicon is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Lexicon Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Lexicon had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Lexicon Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(228 K)(95 K)(70 K)10.93 M(1.22 M)(1.25 M)
Depreciation Amortization and Accretion3.4 M3.68 M3.65 M2.93 M292 K299.68 K
Net Cash Flow or Change in Cash and Cash Equivalents15.06 M18.73 M(44.27 M)90.15 M(62.2 M)(63.83 M)
Issuance Purchase of Equity Shares6.31 M(240 K)(941 K)68.94 M34.41 M37.68 M
Issuance Repayment of Debt Securities143.62 M(2 M)(1.28 M)(216.58 M)(11.7 M)(12.01 M)
Net Cash Flow from Financing149.93 M(2.24 M)(2.23 M)(147.64 M)22.71 M23.31 M
Net Cash Flow from Investing50.52 M169.58 M(155.85 M)380.76 M2.11 M2.17 M
Net Cash Flow Investment Acquisitions and Disposals50.75 M169.67 M(155.78 M)209.44 M3.33 M3.42 M
Net Cash Flow from Operations(185.39 M)(148.61 M)113.81 M(142.97 M)(87.02 M)(93.89 M)
Share Based Compensation9.47 M11.7 M14.22 M13.27 M10.58 M10.84 M

Lexicon Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Lexicon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Lexicon Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lexicon Pharmaceuticals competition to find correlations between indicators driving Lexicon Pharmaceuticals's intrinsic value. More Info.
Lexicon Pharmaceuticals is considered the number one company in revenue category among related companies. It is currently regarded as number one stock in price to sales category among related companies fabricating about  0.01  of Price to Sales per Revenue. The ratio of Revenue to Price to Sales for Lexicon Pharmaceuticals is roughly  92.23 . Lexicon Pharmaceuticals Revenues is fairly stable at the moment as compared to the past year. Lexicon Pharmaceuticals reported Revenues of 298,000 in 2021. Comparative valuation analysis is a catch-all model that can be used if you cannot value Lexicon Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lexicon Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexicon Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Lexicon Pharmaceuticals Systematic Risk

Lexicon Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lexicon Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Lexicon Pharmaceuticals correlated with the market. If Beta is less than 0 Lexicon Pharmaceuticals generally moves in the opposite direction as compared to the market. If Lexicon Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lexicon Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lexicon Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Lexicon Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
.

About Lexicon Pharmaceuticals Financials

What exactly are Lexicon Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Lexicon Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Lexicon Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Lexicon Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Lexicon Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lexicon Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Lexicon Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Lexicon has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Lexicon Pharmaceuticals December 2, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Lexicon Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lexicon Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lexicon Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Lexicon Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lexicon Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio(0.10)
Maximum Drawdown19.45
Value At Risk(6.08)
Potential Upside5.8
Additionally, see Correlation Analysis. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for analysis

When running Lexicon Pharmaceuticals price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
(0.63) 
Market Capitalization
403.9 M
Quarterly Revenue Growth YOY
0.7
Return On Assets
(0.33) 
Return On Equity
(0.69) 
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Lexicon Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.